We established a xenogeneic model of AML in NOD/Shi‐scid IL2rγnull (NOG) mice to verify the anti‐leukemic capacity of CD44v6 CAR‐T against constructed FLT3 mutated AML cells in vivo. The gene discussed is FLT3; the disease is acute myeloid leukemia.